Feed KMDA
KM

Kamada Ltd.

KMDA · NASDAQ

$8.67 +3.09% (+$0.26)
1M +9.89%
Market Cap $500.2M
P/E Ratio 22.48x
Div. Yield 4.84%
ROE 8.37%

Bulios Fair Price

$12.12

39.8% upside

Trenutna cena

$8.67

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica KMDA trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
6/9
Valuation
70 /100
Cheap
P/E 22.48x
EV/EBITDA 11.50x
P/S 2.61x
Growth
51 /100
Stable
Rev. growth 11.74%
FCF growth 11.94%
Book val. growth 15.20%
Profitability
74 /100
Strong
Gross margin 40.82%
Net margin 11.60%
Op. margin 14.51%
Quality
41 /100
Average
ROIC 6.90%
ROE 8.37%
ROA 5.81%
Debt
100 /100
Low
Debt/Equity 0.04x
Current ratio 4.06x
Int. coverage 25.72x
Stability
38 /100
Moderate
Beta 0.14x
Rev. volatility 1.41%
EPS volatility 192.05%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o KMDA
Online

O podjetju

Kamada Ltd. (KMDA) is a biopharmaceutical company engaged in research, development, and manufacturing of therapeutic products. The company specializes in the development and production of protein therapeutics and immunoglobulins for various therapeutic applications. Kamada has developed a range of biological therapeutics and products aimed at treating rare and genetic diseases, including immune deficiencies and hematological disorders. With its innovative products and meticulous research, the company maintains a significant position in the biopharmaceutical sector. Kamada Ltd. (KMDA) also has extensive collaborations with international pharmaceutical companies for the distribution of its therapeutics and the development of new treatment possibilities. Kamada Ltd. (KMDA) shares may be an attractive investment opportunity for investors interested in the biopharmaceutical sector and seeking an investment in a company with an innovative portfolio of therapeutics and potential for further growth in treatment technologies.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Amir London

Employees

462

Headquarters

Rehovot

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

52d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.